Expression of CD45, CD34, CD10, and human leukocyte antigen‑DR in acute lymphoblastic leukemia


BACKGROUND: Immunophenotypic analysis of leukemic cells by multicolor flow cytometry usingdifferent monoclonal antibodies labeled to various flourochromes, is an important, precise and rapidinvestigation for diagnosis, classification, prognosis prediction, and minimal residual disease detectionin acute lymphoblastic leukemia (ALL).OBJECTIVES: The aims of study were to study the expression of CD45, CD34, CD10, humanleukocyte antigen‑DR (HLA‑DR) in B and T‑ALL among 114 Iraqi patients and compare findingswith other reports worldwide.PATIENTS, MATERIALS AND METHODS: A retrospective cross‑sectional study was conductedon 114 ALL patients of various age groups from different hematology centers in Baghdad who werereferred to Flowcytometry Department at the Bone Marrow Transplantation Center/Private NursingHome Hospital/Medical City for immunophenotypic classification using multi‑color flow cytometryfrom the January 1, 2016, to the August 31, 2016.RESULTS: Out of 114 patients, 71 patients were pediatric patients and 43 were adults. Eighty‑threepatients were classified as B‑cell ALL and 31 patients as T‑cell ALL. There was significant associationbetween male gender, high white blood cells count and T‑cell ALL subtype. Negative‑dim‑moderateCD45, positive CD34, and positive HLA‑DR expressions were significantly associated with B‑cellALL. Common ALL antigen was seen in 86.7% of the B‑cell ALL patients and was accompaniedcTdT expression. Aberrant myeloid antigens were observed in 22.9% of B‑cell ALL patients and in35.5% of T‑cell ALL. About 4.8% of the patients with B‑cell ALL had aberrant T‑linage antigens while6.5% of the patients with T‑cell ALL expressed aberrant B‑cell lineage antigens.CONCLUSION: Immunophenotypic expression of ALL cells among Iraqi patients is to somewhat inaccordance with various researches worldwide making immunophenotyping flow cytometry a crucialappliance in diagnosis, classification, risk stratification, and minimal residual disease detection in ALL